There are 702 resources available
395MO - Tislelizumab (TIS) + chemotherapy (CT) vs placebo (PBO) + CT in advanced or metastatic esophageal squamous cell carcinoma (ESCC): PD-L1 biomarker analysis from RATIONALE-306
Presenter: Eric Raymond
Session: Mini Oral session 3
Resources:
Abstract
Slides
Webcast
396MO - Anti-claudin 18.2 (CLDN18.2) antibody-drug conjugate (ADC) IBI343 in patients (pts) with solid tumors and gastric/gastro-esophageal junction adenocarcinoma (G/GEJ AC): A phase I study
Presenter: Jia Jenny Liu
Session: Mini Oral session 3
Resources:
Abstract
Slides
Webcast
397MO - Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT in HER2-negative advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma (GC/GEJC): PD-L1 biomarker analysis from RATIONALE-305
Presenter: Markus Moehler
Session: Mini Oral session 3
Resources:
Abstract
Slides
Webcast
Invited discussant abstracts 395MO, 396MO and 397MO
Presenter: David Ilson
Session: Mini Oral session 3
Resources:
Slides
Webcast
Q&A and discussion
Session: Mini Oral session 3
Resources:
Webcast
Keynote lecture: Ten years of improvement in the treatment of liver cancer
Presenter: Stephen Chan
Session: ESMO GI 2024 Keynote and take-home messages
Resources:
Slides
Webcast
How to integrate patient perspectives in GI cancer management and research
Presenter: Zorana Maravic
Session: ESMO GI 2024 Keynote and take-home messages
Resources:
Slides
Webcast
Colorectal cancer
Presenter: Eric Van Cutsem
Session: ESMO GI 2024 Keynote and take-home messages
Resources:
Slides
Webcast
Hepatopancreaticobiliary cancer
Presenter: Teresa Macarulla Mercade
Session: ESMO GI 2024 Keynote and take-home messages
Resources:
Slides
Webcast
Upper GI cancers
Presenter: Michel Ducreux
Session: ESMO GI 2024 Keynote and take-home messages
Resources:
Slides
Webcast